Format

Send to

Choose Destination
Antiviral Res. 2014 Jan;101:26-9. doi: 10.1016/j.antiviral.2013.10.012. Epub 2013 Oct 30.

Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters.

Author information

1
Viral Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: mko2@cdc.gov.
2
Viral Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States.
3
Department of Pathology, Yale University School of Medicine, New Haven, CT, United States.
4
Infectious Disease Pathology Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States.
5
Viral Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: ccs8@cdc.gov.

Abstract

Nipah virus (NiV) continues to cause outbreaks of fatal human encephalitis due to spillover from its bat reservoir. We determined that a single dose of replication-defective vesicular stomatitis virus (VSV)-based vaccine vectors expressing either the NiV fusion (F) or attachment (G) glycoproteins protected hamsters from over 1000 times LD50 NiV challenge. This highly effective single-dose protection coupled with an enhanced safety profile makes these candidates ideal for potential use in livestock and humans.

KEYWORDS:

Hamster; Henipavirus; Nipah; Single-dose; VSV; Vaccine

PMID:
24184127
PMCID:
PMC3874889
DOI:
10.1016/j.antiviral.2013.10.012
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center